Sellas’ GPS vaccine cuts death risk 41% in phase 3 AML trial
SLS•Sellas Life Sciences said its phase 3 REGAL trial met its primary endpoint, with galinpepimut-S improving overall survival versus best available treatment and cutting death risk 41%. The company said it will discuss an accelerated filing strategy with the FDA and is preparing a Biologics License Application for the first half of 2027.




